Sarepta Therapeutics, Inc. drugs

4 results

  • amondys 45- casimersen injection

    (Casimersen)
    Sarepta Therapeutics, Inc.
    AMONDYS 45 treats Duchenne muscular dystrophy (DMD) in patients with a confirmed DMD gene mutation amenable to exon 45 skipping. Approved under accelerated approval based on increased dystrophin production in skeletal muscle; continued approval contingent on confirmatory trial results.
    Medication Details

  • exondys 51- eteplirsen injection

    (Eteplirsen)
    Sarepta Therapeutics, Inc.
    Exondys 51 treats Duchenne muscular dystrophy (DMD) in patients with a confirmed DMD gene mutation amenable to exon 51 skipping. Approved under accelerated approval based on observed dystrophin increases; continued approval contingent on confirmatory trial results.
    Medication Details

  • vyondys 53- golodirsen injection

    (Golodirsen)
    Sarepta Therapeutics, Inc.
    Vyondys 53 treats Duchenne muscular dystrophy (DMD) in patients with a confirmed DMD gene mutation amenable to exon 53 skipping. Approved under accelerated approval based on increased dystrophin production in skeletal muscle; continued approval may depend on confirmatory trial results.
    Medication Details
    Drug Interactions